Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
暂无分享,去创建一个
M. Friedrich | P. Hoffmann | R. Kischel | P. Kufer | R. Lutterbuese | T. Raum | B. Rattel | D. Zopf | P. Baeuerle | M. Voelkel | P. Deegen | Doris Rau | C. Brandl | J. Schuhmacher | P. Mueller | R. Finnern | Melanie Fuergut | J. Slootstra | Tobias Raum | Petra Deegen
[1] F. Hamdy,et al. Current vaccination strategies for prostate cancer. , 2012, European urology.
[2] Hermann Einsele,et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] U. Wetterauer,et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single‐chain diabody , 2011, The Prostate.
[4] A. Korman,et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. , 2010, Seminars in oncology.
[5] M. Friedrich,et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells , 2010, Proceedings of the National Academy of Sciences.
[6] U. Wetterauer,et al. Target-dependent T-cell Activation by Coligation With a PSMA×CD3 Diabody Induces Lysis of Prostate Cancer Cells , 2009, Journal of immunotherapy.
[7] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[8] P. Wolf,et al. Targeted therapies for prostate cancer against the prostate specific membrane antigen. , 2009, Current drug targets.
[9] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[10] P. Kufer,et al. Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class , 2007 .
[11] Aza A Mohammed,et al. ProstaScint™ and its role in the diagnosis of prostate cancer , 2007, Expert review of molecular diagnostics.
[12] U. Wetterauer,et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells , 2007, Cancer Immunology, Immunotherapy.
[13] E. Klein,et al. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. , 2007, European urology.
[14] P. Kufer,et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. , 2006, Journal of immunotherapy.
[15] P. Parren,et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.
[16] Mindy I. Davis,et al. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Moul,et al. Rising prostate-specific antigen after primary prostate cancer therapy , 2005, Nature Clinical Practice Urology.
[18] Yannick Jacques,et al. Identification of an Interleukin-15α Receptor-binding Site on Human Interleukin-15* , 2004, Journal of Biological Chemistry.
[19] P. Kufer,et al. Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens , 2001, Cancer Immunology, Immunotherapy.
[20] E. Meinl,et al. Herpesvirus saimiri-transformed macaque T cells are tolerated and do not cause lymphoma after autologous reinfusion. , 2000, Blood.
[21] M. Little,et al. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. , 1997, Protein engineering.
[22] G. Ligtvoet,et al. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries , 1996, Molecular Diversity.
[23] L. Benet,et al. Noncompartmental determination of the steady-state volume of distribution. , 1979, Journal of pharmaceutical sciences.
[24] Kiyoshi Yamaoka,et al. Statistical moments in pharmacokinetics , 1978, Journal of Pharmacokinetics and Biopharmaceutics.
[25] L. Fletcher,et al. Error bars represent standard error of mean , 2011 .
[26] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[27] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.